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LETTERS TO THE EDITOR
Improved Endothelial Function With
Metformin in Type 2 Diabetes Mellitus
Although the idea that metformin could improve endothelial
function in humans is not new (1), Mather et al. (2) are to be
congratulated in providing the first in vivo evidence that, in type 2
diabetic patients, metformin therapy for 12 weeks significantly
improved acetylcholine-stimulated, endothelium-dependent vaso-
dilation compared to placebo. They postulated potential mecha-
nisms for metformin’s beneficial effects (other than glucose-
lowering), including reduction in insulin resistance, antioxidant
effects, favorable effects on lipids and free fatty acids as well as
direct vasodilative effects (2). I would like to suggest an additional
mechanism that might have important clinical implications.
Over recent years, there is growing evidence that accumulation
of advanced glycation end products (AGEs) in hyperglycemic
states plays a dominant role in endothelial dysfunction, which
could lead to diabetic vasculopathy (3). Glycation is a nonenzy-
matic, posttranslational modification of protein, resulting from
chemical reactions between glucose and primary amino acids.
-Dicarbonyl molecules such as methylglyoxal (MG) and
3-deoxyglucosone are precursors of AGEs, which are increased in
diabetes. It has been shown that metformin reduces MG in vitro
(4). Similarly, in diabetic subjects treated with metformin, plasma
MG concentrations are significantly lower compared with those
treated with diet, sulfonylurea or insulin (5). This effect is
independent of glycemic control. This novel mechanism provides
the rationale of potential use of metformin (in addition to insulin)
to reduce vascular complications in type 1 diabetes. Large-scale
randomized control trials will be required to test this hypothesis.
Furthermore, other inhibitors of glycation, such as aminoguani-
dine, in conjunction with conventional antihyperglycemic treat-
ment for type 2 diabetes, may confer additional benefits in
reduction of vascular complications.
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REPLY
We appreciate Dr. Chan’s interest in our study, and we thank him
for pointing out this additional potential mechanism for the
beneficial effect of metformin in the vasculature. On the surface, it
may seem unlikely that changes in advanced glycosylation end
products (AGEs) would account for the findings in our study,
given both the relatively short duration of therapy and the
generally good glycemic control of our subjects at study entry
(HbAc  7%) (1).
However, as Dr. Chan correctly points out, favorable effects of
metformin on the levels of precursors of AGE such as methylg-
lyoxal have been noted (2,3). These intermediates have been
postulated to contribute to a state of “carbonyl stress” analogous to,
but distinct from, the oxidative stress engendered by AGEs acting
in part through specific cell-surface receptors for AGEs (4).
Although the dynamics of these intermediates are less clearly
understood than those of the end products, it is reasonable to
expect that such molecules are present in elevated concentrations in
proportion to ambient glycemia (3). Although AGEs have been
linked with impairments in endothelial function (5–7), no analo-
gous evidence documenting a relationship with the precursor
intermediates is available in the literature. Of course, these
intermediates have most likely been present in studies of hyper-
glycemia and endothelial function, including those specifically
addressing AGEs, and they may well have contributed to the
observed impairments in endothelial function. However, firm
connection remains to be established between carbonyl compounds
such as methylglyoxal and endothelial dysfunction.
Unfortunately, we were unable to quantitate either oxidative
stress or any of these carbonyl compounds in conjunction with our
therapy and cannot comment on the potential relationship to the
improved vascular function. As detailed in the Discussion section
of our paper (1), the mechanism of vascular benefit of metformin
in our study remains unexplained. We agree that this potential
mechanism for the vascular benefit of metformin warrants further
investigation and may be of relevance in both type 1 and type 2
diabetes mellitus.
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